PARKINSON DISEASE (Disorder)Phase 2Vista PDNCT07804615
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
A Phase 2 study testing VIM0423 in people with PARKINSON DISEASE (Disorder), run by Vima Therapeutics at 30 sites in 2 countries.
Trial summary
Vista PD is a randomized, placebo-controlled, multicenter study to evaluate the efficacy, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- PARKINSON DISEASE (Disorder)
- What is being tested?
- VIM0423
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 30 sitesin 2 countries
- Study dates
- Sep 2026to Jun 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant must be male or nonpregnant female between 18 and 65 years of age (inclusive) at Visit 1 (Screening).
- Diagnosis of clinically probable or clinically established idiopathic Parkinson's disease (PD) at Visit 1 (Screening) established by the MDS 2015 criteria which must include tremor as one of the cardinal characteristics.
- Cohort 1: Currently using levodopa (any oral form only) or oral dopamine agonist at a stable dose and regimen of at least 10 weeks prior to Visit 1 (Screening); with no anticipated changes to said therapies for the duration of the study; and on a minimum of 300 mg LEDD. Cohort 2: Individuals who are dopaminergic naïve, as defined by: no prior or ongoing usage of levodopa (in any form) or dopamine agonist (in any form), and no anticipated plans to initiate said therapies for the duration of the study.
- The participants must meet protocol-specified requirements for baseline tremor scores.
Who cannot join
- Currently (within 7 days of Screening) taking any anticholinergic medication.
- Prior deep brain stimulation (DBS) or any other form of invasive neurosurgical intervention (including, but not limited to, magnetic resonance-guided focused ultrasound thalamotomy, ablative thalamotomy, gamma knife thalamotomy)
- Other protocol-specified inclusion and exclusion criteria may apply.
Trial locations and contacts
30 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
30 sites in 2 countries
United States29 sites, 29 recruiting
- Not yet recruiting
Vima Site #014
Albuquerque, New Mexico, 87106
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #065
Altamonte Springs, Florida, 32714
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #055
Amherst, New York, 14226
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #066
Arlington, Virginia, 22205
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #047
Atlanta, Georgia, 30328
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #054
Aventura, Florida, 33180
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #043
Baltimore, Maryland, 21237
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #051
Canton, Ohio, 44718
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #049
Cypress, Texas, 77429
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #063
Dallas, Texas, 75243
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #045
Decatur, Georgia, 30030
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Recruiting
Vima Site #002
Farmington Hills, Michigan, 48334
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #023
Kirkland, Washington, 98034
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #016
Memphis, Tennessee, 38157
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #008
Miami, Florida, 33176
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #048
Murrieta, California, 92562
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #046
Naples, Florida, 34105
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #024
New York, New York, 10019
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #007
Olney, Maryland, 20832
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #041
Overland Park, Kansas, 66211
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #053
Palm Beach, Florida, 33407
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #052
Patchogue, New York, 11772
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #067
Raleigh, North Carolina, 27607
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #058
Round Rock, Texas, 78681
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #039
Scottsdale, Arizona, 85251
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #064
Scottsdale, Arizona, 85258
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #015
Spokane, Washington, 99202
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #050
Stamford, Connecticut, 06905
Study Director, 617-430-7027, clinicaltrials@vimatx.com
- Not yet recruiting
Vima Site #062
Tampa, Florida, 33602
Study Director, 617-430-7027, clinicaltrials@vimatx.com
Canada1 site, 1 recruiting
- Not yet recruiting
Vima Site #060
Toronto, Ontario, M5G 2C4
Study Director, 617-430-7027, clinicaltrials@vimatx.com
About this study
Official title: A Phase 2 Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
Vista PD is a randomized, placebo-controlled, multicenter study to evaluate the efficacy, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy.
The main objectives of this clinical trial are to determine the following:
- Does VIM0423 therapy improve tremor symptoms in adults with Parkinson's disease?
- Is VIM0423 well tolerated in individuals with Parkinsons's disease? and
- Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?
Read the detailed description
Parkinson's disease (PD) is the second most common neurodegenerative condition, with studies estimating US prevalence among individuals aged 45 years and older rising to approximately 1,238,000 by 2030. More than 75% of individuals with PD will experience resting tremor at some point during their disease course, and approximately 60% additionally suffer from a symptomatic tremor during action or movement, complicating functional tasks.
The distress caused by PD tremor is profound, with individuals consistently identifying it as their "most bothersome" symptom in early disease, and more impactful than other motor and nonmotor symptoms. Despite the clear importance of this symptom to patient experience, significant unmet need in tremor management persists. Tremor-specific efficacy of dopaminergic therapy, the mainstay of early PD pharmacology, is often inconsistent or incomplete, giving rise to the clinical concept of "dopamine-responsive" versus "dopamine-refractory" tremor. Anti-tremor efficacy of anticholinergic agents has been recognized for decades; however, their clinical utility is limited by both central and peripheral adverse effects VIM0423 is being developed as an oral medication designed to improve the central and peripheral tolerability seen with other anticholinergic medications.
Vista PD (Study VIM0423-251) is a Phase 2, multicenter study designed to assess the efficacy, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy. Up to 80 individuals will be enrolled in the trial.
Cohort 1 will be comprised of adults diagnosed with PD who are on stable and adequate dopaminergic therapy (oral levodopa or oral dopamine agonist only), with residual tremor. Participants in Cohort 1 will be randomized (1:1) to receive either VIM0423 or matching placebo (up to 5 pills a day[MO1.1][TG1.2][MO1.3], taken once daily) for 7 weeks. The Investigator and Participant will not know whether [MO2.1]patients are receiving VIM0423 or placebo, but that information will be available if needed.
Cohort 2 will be comprised of adults diagnosed with PD who are dopaminergic naïve, as defined by: no prior or ongoing usage of levodopa (in any form) or dopamine agonist (in any form), and no anticipated plans to initiate said therapies for the duration of the study. Participants in Cohort 2 will be randomized (1:1) to receive either VIM0423 or matching placebo (up to 5 pills a day[MO3.1], taken once daily) for 7 weeks. The Investigator and Participant will not know whether patients are receiving VIM0423 or placebo, but that information will be available if needed.
The total time of participation in the trial is up to 12 weeks and requires 6 in person visits. The study schedule includes Screening and Baseline (up to 4 weeks, 2 visits), Treatment period (including taper, 7 weeks, 3 Visits), and Safety follow-up (1 week, 1 Visit).
Assessments of changes in Parkinson's disease will be made by study personnel. Clinical labs, EKGs, and Adverse events will be monitored throughout the study. Participants will be asked to use a wearable device during the study and perform self-assessments of their Parkinson's tremor and its impact on their activities of daily living.
- Conditions
- PARKINSON DISEASE (Disorder)
- Being tested
- VIM0423, VIM0423 Placebo
- Keywords
- Parkinsonian Disorders, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Parkinson Disease, Tremor, Movement Disorder
- Medical subject headings
- Parkinson Disease, Parkinsonian Disorders, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Tremor, Movement Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VIM0423Drug
VIM0423 is a combination drug product containing two active ingredients (VMA-1001 and VMA-1002)
VIM0423 PlaceboDrug
Matching VIM0423 placebo product containing no active ingredient
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1 | Active comparator | Participants receiving active (VIM0423) n~25 Receives: Drug: VIM0423 |
| Cohort 1 Placebo | Placebo comparator | Participants receiving placebo n~25 Receives: Drug: VIM0423 Placebo |
| Cohort 2 | Active comparator | Participants receiving active (VIM0423) n~15 Receives: Drug: VIM0423 |
| Cohort 2 Placebo | Placebo comparator | Participants receiving placebo n~15 Receives: Drug: VIM0423 Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
The MDS-UPDRS is a multi-part assessment designed to evaluate various aspects of PD and its impact on the individual, including motor and non-motor symptoms. There are four parts, all of which will be completed in this study: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living), Part III (motor examination), and Part IV (motor complications). Each part has varying maximum scores. In all cases, a higher score represents a more severe status.
Measured: From baseline to Week 6
Secondary outcomes (5)
Change from baseline in Clinical Global Impression of Severity (CGI-S) as assessed by the clinician
The CGI-S assesses the clinician's impression of the participant's current illness state. The clinician should use his/her total clinical experience with this population and rate the current severity of the participant's PD on a scale from 1 (normal, not at all ill) to 7 (among the most extremely ill).
Measured: From baseline to Week 6
Change from baseline in Tremor Research Group Essential Tremor Rating Scale - Activities of Daily Living (TETRAS-ADL)
The TETRAS-ADL is a standardized assessment of the impact of tremor on activities of daily living in individuals with essential tremor. There are 12 items: speaking; feeding with a spoon; drinking from a glass; hygiene; dressing; pouring; carrying food on trays, plates or similar items; using keys; writing; working; overall disability; social impact. Each item is scored 0 (normal) to 4 (severe/severely abnormal), for a total possible score of 48, with a higher score indicated a worse impact of tremor.
Measured: From baseline to Week 6
Clinical Global Impression of Change (CGI-C)
The CGI-C assesses the clinician's impression of how the participant's current illness has changed relative to baseline/pre-study. The clinician should use his/her total clinical experience with the individual participant and rate the participant's change in signs and reported symptoms using the scale: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), or 7 (very much worse).
Measured: From baseline to Week 6
Patient Global Impression of Change (PGI-C)
The PGI-C is a written scale which will be used to solicit the participant's self-report of overall difference in PD related symptoms compared to his/her pre-study baseline. The score for each timepoint will be: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), or 7 (very much worse).
Measured: From baseline to Week 6
Change from baseline in Scales for Outcomes in Parkinson's Disease (SCOPA) - Sleep
The SCOPA-Sleep is a validated patient-completed scale for assessing various components of sleep in individuals with PD: use of medication for sleep (2 items), nighttime sleep (5 items), global evaluation of sleep (1 item), and daytime sleepiness (6 items). A higher score represents a worse outcome.
Measured: From baseline to Week 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Sep 2026
- Study startSep 2026 (estimated)
- Primary completionJun 2027 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PARKINSON DISEASE (Disorder)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Parallel cohorts of participants receiving active or placebo drug products
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vima Therapeutics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07804615
- Sponsor's protocol ID
- VIM0423-251
- Acronym
- Vista PD
- Status last verified
- Aug 2026
- First submitted
- 31 Aug 2026
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2 Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
- ClinicalTrials.gov ID
- NCT07804615
- Acronym / sponsor ID
- Vista PD / VIM0423-251
- Conditions
- PARKINSON DISEASE (Disorder)
- Keywords
- Parkinsonian Disorders, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Parkinson Disease, Tremor, Movement Disorder
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Vima TherapeuticsIndustry (pharma, biotech, devices)
- Study start
- Sep 2026 (estimated)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 4 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Vista PD is a randomized, placebo-controlled, multicenter study to evaluate the efficacy, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy.
The main objectives of this clinical trial are to determine the following:
- Does VIM0423 therapy improve tremor symptoms in adults with Parkinson's disease?
- Is VIM0423 well tolerated in individuals with Parkinsons's disease? and
- Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?
Detailed description
Parkinson's disease (PD) is the second most common neurodegenerative condition, with studies estimating US prevalence among individuals aged 45 years and older rising to approximately 1,238,000 by 2030. More than 75% of individuals with PD will experience resting tremor at some point during their disease course, and approximately 60% additionally suffer from a symptomatic tremor during action or movement, complicating functional tasks.
The distress caused by PD tremor is profound, with individuals consistently identifying it as their "most bothersome" symptom in early disease, and more impactful than other motor and nonmotor symptoms. Despite the clear importance of this symptom to patient experience, significant unmet need in tremor management persists. Tremor-specific efficacy of dopaminergic therapy, the mainstay of early PD pharmacology, is often inconsistent or incomplete, giving rise to the clinical concept of "dopamine-responsive" versus "dopamine-refractory" tremor. Anti-tremor efficacy of anticholinergic agents has been recognized for decades; however, their clinical utility is limited by both central and peripheral adverse effects VIM0423 is being developed as an oral medication designed to improve the central and peripheral tolerability seen with other anticholinergic medications.
Vista PD (Study VIM0423-251) is a Phase 2, multicenter study designed to assess the efficacy, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy. Up to 80 individuals will be enrolled in the trial.
Cohort 1 will be comprised of adults diagnosed with PD who are on stable and adequate dopaminergic therapy (oral levodopa or oral dopamine agonist only), with residual tremor. Participants in Cohort 1 will be randomized (1:1) to receive either VIM0423 or matching placebo (up to 5 pills a day[MO1.1][TG1.2][MO1.3], taken once daily) for 7 weeks. The Investigator and Participant will not know whether [MO2.1]patients are receiving VIM0423 or placebo, but that information will be available if needed.
Cohort 2 will be comprised of adults diagnosed with PD who are dopaminergic naïve, as defined by: no prior or ongoing usage of levodopa (in any form) or dopamine agonist (in any form), and no anticipated plans to initiate said therapies for the duration of the study. Participants in Cohort 2 will be randomized (1:1) to receive either VIM0423 or matching placebo (up to 5 pills a day[MO3.1], taken once daily) for 7 weeks. The Investigator and Participant will not know whether patients are receiving VIM0423 or placebo, but that information will be available if needed.
The total time of participation in the trial is up to 12 weeks and requires 6 in person visits. The study schedule includes Screening and Baseline (up to 4 weeks, 2 visits), Treatment period (including taper, 7 weeks, 3 Visits), and Safety follow-up (1 week, 1 Visit).
Assessments of changes in Parkinson's disease will be made by study personnel. Clinical labs, EKGs, and Adverse events will be monitored throughout the study. Participants will be asked to use a wearable device during the study and perform self-assessments of their Parkinson's tremor and its impact on their activities of daily living.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- Parallel cohorts of participants receiving active or placebo drug products
| Arm | Type | Receives |
|---|---|---|
| Cohort 1 | Active comparator | Drug: VIM0423Participants receiving active (VIM0423) n~25 |
| Cohort 1 Placebo | Placebo comparator | Drug: VIM0423 PlaceboParticipants receiving placebo n~25 |
| Cohort 2 | Active comparator | Drug: VIM0423Participants receiving active (VIM0423) n~15 |
| Cohort 2 Placebo | Placebo comparator | Drug: VIM0423 PlaceboParticipants receiving placebo n~15 |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Participant must be male or nonpregnant female between 18 and 65 years of age (inclusive) at Visit 1 (Screening).
- Diagnosis of clinically probable or clinically established idiopathic Parkinson's disease (PD) at Visit 1 (Screening) established by the MDS 2015 criteria which must include tremor as one of the cardinal characteristics.
- Cohort 1: Currently using levodopa (any oral form only) or oral dopamine agonist at a stable dose and regimen of at least 10 weeks prior to Visit 1 (Screening); with no anticipated changes to said therapies for the duration of the study; and on a minimum of 300 mg LEDD. Cohort 2: Individuals who are dopaminergic naïve, as defined by: no prior or ongoing usage of levodopa (in any form) or dopamine agonist (in any form), and no anticipated plans to initiate said therapies for the duration of the study.
- The participants must meet protocol-specified requirements for baseline tremor scores.
Key exclusion criteria (3 listed)
- Currently (within 7 days of Screening) taking any anticholinergic medication.
- Prior deep brain stimulation (DBS) or any other form of invasive neurosurgical intervention (including, but not limited to, magnetic resonance-guided focused ultrasound thalamotomy, ablative thalamotomy, gamma knife thalamotomy)
- Other protocol-specified inclusion and exclusion criteria may apply.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VIM0423VIM0423 is a combination drug product containing two active ingredients (VMA-1001 and VMA-1002) | Drug | Cohort 1, Cohort 2 |
| VIM0423 PlaceboMatching VIM0423 placebo product containing no active ingredient | Drug | Cohort 1 Placebo, Cohort 2 Placebo |
Primary outcome
Change from baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Time frame: From baseline to Week 6
The MDS-UPDRS is a multi-part assessment designed to evaluate various aspects of PD and its impact on the individual, including motor and non-motor symptoms. There are four parts, all of which will be completed in this study: Part I (non-motor experiences of daily living), Part II (motor experiences of daily living), Part III (motor examination), and Part IV (motor complications). Each part has varying maximum scores. In all cases, a higher score represents a more severe status.
5 secondary outcomes
Change from baseline in Clinical Global Impression of Severity (CGI-S) as assessed by the clinician
Time frame: From baseline to Week 6
Change from baseline in Tremor Research Group Essential Tremor Rating Scale - Activities of Daily Living (TETRAS-ADL)
Time frame: From baseline to Week 6
Clinical Global Impression of Change (CGI-C)
Time frame: From baseline to Week 6
Patient Global Impression of Change (PGI-C)
Time frame: From baseline to Week 6
Change from baseline in Scales for Outcomes in Parkinson's Disease (SCOPA) - Sleep
Time frame: From baseline to Week 6
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for PARKINSON DISEASE (Disorder)
Active, not recruitingPhase 2
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Thymoma, Thymic Carcinoma
RecruitingPhase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Recruiting
Decoding the Neural Mechanisms Underlying Postural Instability and Gait Dysfunction in Parkinson's Disease
Parkinson Disease, Freezing of Gait
Enrolling by invitationPhase 1/2
Lithium for Parkinson's: an Extension Trial
Parkinson Disease
Recruiting
Genetics and Aerobic Exercise to Slow Parkinson's Disease Trial
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
30 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing VIM0423 in people with PARKINSON DISEASE (Disorder), run by Vima Therapeutics at 30 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 30 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Study Director (617-430-7027, Clinicaltrials@vimatx.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (time frame: From baseline to Week 6). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.